Cargando…

Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients

Oxidative stress caused by free radicals has been implicated in the pathogenesis of amyotrophic lateral sclerosis (ALS). Edaravone (also known as MCI-186), a free radical scavenger, was approved as an ALS treatment in 2015 in Japan. However, the therapeutic effects of edaravone on patients with ALS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Jin-Mo, Kim, Sun-Young, Park, Donghwi, Park, Jin-Sung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223963/ https://www.ncbi.nlm.nih.gov/pubmed/31471712 http://dx.doi.org/10.1007/s10072-019-04055-3

Ejemplares similares

Long-term outcomes of edaravone in amyotrophic lateral sclerosis in South Korea: 72-week observational study
por: Park, Jin-Mo, et al.
Publicado: (2022)

Investigating Edaravone Use for Management of Amyotrophic Lateral Sclerosis (ALS): A Narrative Review
por: Neupane, Purushottam, et al.
Publicado: (2023)

Long-term effects of edaravone on survival of patients with amyotrophic lateral sclerosis
por: Okada, Masamitsu, et al.
Publicado: (2018)

Ethnical Disparities in Response to Edaravone in Patients With Amyotrophic Lateral Sclerosis
por: Jayasinghe, Maleesha, et al.
Publicado: (2022)

Magnetic resonance metrics to evaluate the effect of therapy in amyotrophic lateral sclerosis: the experience with edaravone
por: Distaso, Eugenio, et al.
Publicado: (2021)

How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis?
por: Watanabe, Kazutoshi, et al.
Publicado: (2018)

Effects of the Edaravone, a Drug Approved for the Treatment of Amyotrophic Lateral Sclerosis, on Mitochondrial Function and Neuroprotection
por: Cha, Sun Joo, et al.
Publicado: (2022)

Role of Edaravone as a Treatment Option for Patients with Amyotrophic Lateral Sclerosis
por: Cho, HaEun, et al.
Publicado: (2020)

Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19
por: Al-Chalabi, Ammar, et al.
Publicado: (2021)

Assessment of Therapeutic Response of Edaravone and Riluzole Combination Therapy in Amyotrophic Lateral Sclerosis Patients
por: Samadhiya, Swapnil, et al.
Publicado: (2022)

The effectiveness of nonsteroidal anti-inflammatory drugs and acetaminophen in reduce the risk of amyotrophic lateral sclerosis? A meta-analysis
por: Chang, Min Cheol, et al.
Publicado: (2020)

Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS): Protocol and Study Design
por: Berry, James, et al.
Publicado: (2021)

Relationship between statins and the risk of amyotrophic lateral sclerosis: A PRISMA-compliant meta-analysis
por: Chang, Min Cheol, et al.
Publicado: (2021)

Serum uric acid level predicts the progression of amyotrophic lateral sclerosis following treatment with edaravone
por: Han, Hee Jo, et al.
Publicado: (2022)

Renal function in amyotrophic lateral sclerosis patients on long-term treatment with edaravone
por: Kakimoto, Asako, et al.
Publicado: (2021)

An analysis of variants in TARDBP in the Korean population with amyotrophic lateral sclerosis: comparison with previous data
por: Sung, Wonjae, et al.
Publicado: (2023)

Can Therapeutic Exercise Slow Down Progressive Functional Decline in Patients With Amyotrophic Lateral Sclerosis? A Meta-Analysis
por: Park, Donghwi, et al.
Publicado: (2020)

Assessment of Use and Safety of Edaravone for Amyotrophic Lateral Sclerosis in the Veterans Affairs Health Care System
por: Vu, Michelle, et al.
Publicado: (2020)

Safety and efficacy of edaravone in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis
por: Nourelden, Anas Zakarya, et al.
Publicado: (2023)

Application of different ventilator modes in patients with amyotrophic lateral sclerosis according to certain clinical situations: A Case Report
por: Park, Donghwi
Publicado: (2017)

Long-Term Outcome of Amyotrophic Lateral Sclerosis in Korean Subjects
por: Suh, Mi Ri, et al.
Publicado: (2017)

Different characteristics of ventilator application between tracheostomy- and noninvasive positive pressure ventilation patients with amyotrophic lateral sclerosis
por: Park, Donghwi, et al.
Publicado: (2017)

Feasibility of high-resolution manometry for decision of feeding methods in patients with amyotrophic lateral sclerosis
por: Suh, Jee Hyun, et al.
Publicado: (2019)

Improved Long-Term Survival with Edaravone Therapy in Patients with Amyotrophic Lateral Sclerosis: A Retrospective Single-Center Study in Japan
por: Houzen, Hideki, et al.
Publicado: (2021)

Usefulness of the Modified Videofluoroscopic Dysphagia Scale in Evaluating Swallowing Function among Patients with Amyotrophic Lateral Sclerosis and Dysphagia
por: Lee, Byung Joo, et al.
Publicado: (2021)

Evidence of Metabolic Dysfunction in Amyotrophic Lateral Sclerosis (ALS) Patients and Animal Models
por: Maksimovic, Katarina, et al.
Publicado: (2023)

Post-Marketing Experience of Edaravone in Amyotrophic Lateral Sclerosis: A Clinical Perspective and Comparison With the Clinical Trials of the Drug
por: Ortiz, Juan Fernando, et al.
Publicado: (2020)

In silico studies reveal structural deviations of mutant profilin-1 and interaction with riluzole and edaravone in amyotrophic lateral sclerosis
por: Sadr, Ahmad Shahir, et al.
Publicado: (2021)

Impaired Perception of Emotional Expression in Amyotrophic Lateral Sclerosis
por: Oh, Seong-il, et al.
Publicado: (2016)

Anticipation and Phenotypic Heterogeneity in Korean Familial Amyotrophic Lateral Sclerosis with Superoxide Dismutase 1 Gene Mutation
por: Kim, Woojun, et al.
Publicado: (2007)

Long‐term edaravone efficacy in amyotrophic lateral sclerosis: Post‐hoc analyses of Study 19 (MCI186‐19)
por: Shefner, Jeremy, et al.
Publicado: (2019)

Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment
por: Genge, Angela, et al.
Publicado: (2022)

25-Hydroxycholesterol is involved in the pathogenesis of amyotrophic lateral sclerosis
por: Kim, Sung-Min, et al.
Publicado: (2017)

Subclinical articulatory changes of vowel parameters in Korean amyotrophic lateral sclerosis patients with perceptually normal voices
por: Kim, Jin-Ah, et al.
Publicado: (2023)

Anti-Inflammatory Effect of Gamisoyo-San in an Animal Model of Amyotrophic Lateral Sclerosis
por: Park, Sunjung, et al.
Publicado: (2018)

Saccadic intrusions in amyotrophic lateral sclerosis (ALS)
por: Becker, Wolfgang, et al.
Publicado: (2019)

Motoneuron firing in amyotrophic lateral sclerosis (ALS)
por: de Carvalho, Mamede, et al.
Publicado: (2014)

Amyotrophic Lateral Sclerosis (ALS) and Adenosine Receptors
por: Sebastião, Ana M., et al.
Publicado: (2018)

A case of celiac disease with neurologic manifestations misdiagnosed as amyotrophic lateral sclerosis
por: Ham, Hyoju, et al.
Publicado: (2017)

Safety and efficacy of edaravone in well-defined Iranian patients with amyotrophic lateral sclerosis: A parallel-group single-blind trial
por: Eishi-Oskouei, Alireza, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kpn41e8hf8teuuju2l4ungid6n